Close menu




April 9th, 2024 | 06:45 CEST

Palantir, Globex Mining, Bayer - The trend is pointing upwards

  • Mining
  • Commodities
  • Gold
  • Silver
  • Pharma
  • Software
Photo credits: pixabay.com

After a successful first quarter of 2024, the DAX and Dow Jones took a well-deserved breather last week. In contrast, the precious metal markets for gold and silver continued their upward trend. Gold also reached new absolute highs of USD 2,354 per ounce. While gold producers such as Barrick Gold and Newmont remained in hibernation, they have been following the rising base price for several weeks now. There is currently also an opportunity for smaller commodity stocks to participate disproportionately in the upward trend.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: PALANTIR TECHNOLOGIES INC | US69608A1088 , GLOBEX MINING ENTPRS INC. | CA3799005093 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Globex Mining - Asset classes with buy signals

    CEO Jack Stoch has been at the helm of the commodities incubator Globex Mining since 1983, focusing on acquiring and optioning properties to partners. Since then, a diversified portfolio of 247 projects has been built up. This includes interests in 123 precious metals, 68 base metals and 56 specialty metals and industrial minerals.

    The gold and silver projects, in particular, are likely to significantly increase the intrinsic value due to the exploding underlying values. If one considers the market capitalization of CAD 51.39 million and subtracts the portfolio of cash, shares and marketable securities of more than CAD 25 million, the value of the almost 250 holdings would be around CAD 26 million. The portfolio's undervaluation is obvious at first glance.

    In addition, Globex Mining receives a regular cash flow through income from license fees, the leasing of mining rights and the pro rata collection of minerals sold by partners. The Company is currently cooperating with around 100 projects with such licensees, who also bear the exploration costs.

    In addition to rising gold and silver prices, the tide is also turning for industrial metals. The copper chart has been pointing upwards for weeks, and metals such as lithium, which are urgently needed for the energy transition, are also currently forming a stable base. The Globex share chart reflects the positive portfolio development. At CAD 0.93, the share price is on the verge of breaking out of an ascending triangle. If this succeeds, the stock should quickly leave the penny stock zone.

    Palantir - Before the next move

    The technical chart development of data analysis specialist Palantir is almost textbook-like. Since the beginning of May last year, the Company's market capitalization rose by around 280% from USD 7.28 to USD 27.50, partly due to the boom in the trending topic of artificial intelligence. The Palantir share has since corrected and further reduced the overbought conditions created by the price jump. A prominent support zone, the annual high of USD 21.85 reached in 2023, has been successfully defended so far.

    The new cooperation agreement with Oracle could result in a push in the share price. The two US companies intend to collaborate on the sale of cloud and AI services, which should once again significantly increase the revenue and profit of the Denver, Colorado-based company.

    One analyst who was not surprised by Palantir's recent rally is Bruce Kamich from TheStreet Pro. Following the Oracle deal, he set a new price target of USD 48. This would mean a potential upside of around 120% on the current share price.

    Bayer - A drop in the ocean

    Despite the positive news over the weekend, the suffering continues for investors of the pharmaceutical and agricultural giant. Nevertheless, the Leverkusen-based company reported a partial success in a legal dispute, which once again concerned the weedkiller Roundup.

    According to court documents filed on Friday, Judge Daniel Green in Jefferson City, Missouri, reduced the damages awarded to the three plaintiffs by a jury from USD 1.5 billion to USD 600 million. Bayer had lost the case against the three plaintiffs in November. The plaintiffs claimed that the long-term use of the weedkiller caused their cancer.

    However, as revealed in the published annual report for the year 2023, this was just one of approximately 54,000 lawsuits related to the weedkiller glyphosate. Thus, the Company is far from resolving this ongoing issue. Accordingly, Bayer shares were only able to recover briefly, but they gave up all their gains again yesterday and were once again at the bottom of the DAX, down 4%. A turnaround looks different!


    The intrinsic value of Globex Mining's portfolio is likely to have developed positively due to the sharp rise in precious metal prices. Meanwhile, analysts see a doubling of the Palantir share price. Bayer celebrated a partial success, but the glyphosate lawsuits will likely continue to weigh on the Company.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

    AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

    • AI
    • Biotechnology
    • Biotech
    • Pharma

    Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

    Read

    Commented by Carsten Mainitz on October 21st, 2025 | 07:40 CEST

    Power Metallic Mines, RENK, BYD – An explosive combination! And the winners are?

    • Mining
    • Copper
    • Nickel
    • Gold
    • CriticalMetals
    • Electromobility
    • Defense

    Many topics are dominating the headlines. Peace in Gaza – and soon in Ukraine? This prospect initially put a significant damper on defense stocks – but only temporarily. After just a few days of correction, prices are already rising again. Gold at an all-time high is another major topic being covered in the media. Meanwhile, the geopolitical shifts we were reluctant to acknowledge for far too long are now catching up with many companies: China is cutting the world off from critical raw materials and rare earths. Read here to find out how investors can identify promising high-potential opportunities in this constellation.

    Read

    Commented by André Will-Laudien on October 21st, 2025 | 07:35 CEST

    Gold USD 4,300 and Silver USD 53 – Buying frenzy at Silver North, First Majestic, Nel ASA, and JinkoSolar

    • Mining
    • Silver
    • Gold
    • renewableenergies
    • Solar
    • Energy

    Silver has been shorted by many investment banks for several years because sufficient supply was available from Mexico and other producing countries. The tide has turned. Over the past 12 months, the precious metal has caught up with its big brother gold, gaining 54%. There are several reasons for the scarcity-driven rally: there are only around 250 active silver mines worldwide, compared to around 1,400 gold mines. In addition, silver has massively expanded its importance as an industrial metal: it is indispensable in high-tech, e-mobility, defense, and medical technology. As a result, less and less physical silver is available to investors, while inventories on the futures markets continue to decline. Now is the time to take a position in silver. Alongside industry giants such as First Majestic, Silver North is among the most promising beneficiaries of the new silver boom.

    Read